
    
      Patients who have no evidence of disease recurrence confirmed by CT and/or MRI and are
      confirmed to meet all eligibility criteria will be randomized 1:1 to durvalumab + Standard of
      care (SoC) chemotherapy or placebo + Standard of care (SoC) chemotherapy arm.

      The primary objective of this study is to assess the efficacy of durvalumab +SoC chemotherapy
      compared to placebo+ SoC chemotherapy in terms of DFS measured in MRD+ patients.
    
  